Topic

Zanzalintinib (XL092) [investigational]

A collection of 36 issues

How to Get Zanzalintinib (XL092) Covered by Cigna in New York: Complete Appeals Guide with Forms and Timelines

Answer Box: Getting Zanzalintinib (XL092) Covered by Cigna in New York Fastest path: Zanzalintinib (XL092) requires prior authorization through Cigna's formulary exception process since it's investigational. Your oncologist must submit clinical rationale documenting medical necessity and failed standard treatments. If denied, file internal appeals within 180

Renewing Zanzalintinib (XL092) Coverage with Humana in Washington: Timeline, Documentation & Appeal Steps

Answer Box: Renewing Zanzalintinib (XL092) Coverage with Humana in Washington Zanzalintinib (XL092) is an investigational drug requiring compassionate use program enrollment through Exelixis, as it's not FDA-approved. Humana typically covers investigational drugs only within clinical trials or approved compassionate use programs. To renew coverage: (1) Confirm continued eligibility

How to Get Zanzalintinib (XL092) Covered by Cigna in Illinois: Coding, Appeals, and Investigational Drug Access

Answer Box: Getting Zanzalintinib (XL092) Covered by Cigna in Illinois Zanzalintinib (XL092) is an investigational drug that Cigna typically doesn't cover outside clinical trials. However, Illinois patients have strong appeal rights. Your fastest path: 1) Submit a formulary exception request with detailed medical necessity documentation, 2) If denied,

If Zanzalintinib (XL092) Isn't Approved by UnitedHealthcare in California: Formulary Alternatives & Exception Paths

Answer Box: Getting Zanzalintinib (XL092) Covered by UnitedHealthcare in California Zanzalintinib (XL092) is investigational and typically not covered by UnitedHealthcare outside clinical trials. Your fastest paths: 1) Request compassionate use through Exelixis (drug provided free), 2) Try covered multi-target TKI alternatives like cabozantinib or lenvatinib with prior authorization, or 3)

Getting Zanzalintinib (XL092) Covered by Cigna in Pennsylvania: Complete Coding and Appeals Guide

Answer Box: Your Path to Coverage Zanzalintinib (XL092) is an investigational cancer drug requiring special approval from Cigna. In Pennsylvania, you'll need: (1) Your doctor submits a prior authorization with clinical trial documentation or compassionate use approval from Exelixis, (2) if denied, file internal appeals within 180 days,

If Zanzalintinib (XL092) Isn't Approved by Blue Cross Blue Shield in Michigan: Clinical Trial Access & Formulary Alternatives

Quick Answer: Getting Zanzalintinib (XL092) Coverage in Michigan Zanzalintinib (XL092) is investigational and not FDA-approved, so Blue Cross Blue Shield of Michigan typically won't cover it outside clinical trials. Your fastest path: 1) Check if you qualify for ongoing STELLAR trials at ClinicalTrials.gov, 2) Request expanded access